Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Table 2 Weighted mean FEV₁ 0–24 h at Week 12

	Study 207608 (mPP population)		Study 207609 (mPP population)		Pooled analysis (ITT population)
	FF/UMEC/VI N = 358	BUD/FOR+TIO N = 362	FF/UMEC/VI N = 354	BUD/FOR+TIO N = 357	FF/UMEC/VI N = 729	BUD/FOR+TIO N = 731
n	282	272	274	277	674	665
LS mean (95% CI), mL	1210 (1191, 1230)	1195 (1175, 1215)	1185 (1163, 1206)	1174 (1153, 1195)	1199 (1185, 1213)	1185 (1171, 1198)
LS mean (SE) change from baseline, mL	45 (26, 65)	30 (10, 50)	39 (18, 61)	29 (7, 50)	42 (29, 56)	28 (14, 42)
Treatment difference (95% CI), mL	15 (−13, 43)		11 (−20, 41)		14 (−5, 34)

n number of patients with analyzable data at the current time point
BUD budesonide; CI confidence interval; FEV₁ forced expiratory volume in 1 s; FF fluticasone furoate; FOR formoterol; ITT intent-to-treat; LS least squares; mPP modified per protocol; SE standard error; TIO tiotropium; UMEC umeclidinium; VI vilanterol

ISSN: 1465-993X